The present invention provides a targeting vector for the treatment of pancreatic cancer. The targeting vector comprises a CD44v6 single-chain antibody for targeting identification of pancreatic cancer cells, and a nanocarrier IONP-PEI, wherein the CD44v6 single-chain antibody is coupled with the nanocarrier IONP-PEI. On the other hand, the present invention provides a nanoparticle for the treatment of pancreatic cancer. The nanoparticle includes an aforementioned targeting vector, a silencing RNA, and a gemcitabine chemotherapeutics, wherein the silencing RNA and gemcitabine are compounded on the aforementioned targeting vector. The present invention constructs an efficient, safe non-viral gene vector with targeting function. The silencing RNA and gemcitabine are coupled by the nanocarrier, and are couple with the anti-CD44v6 single chain antibody, so as to realize combined application of gene therapy, chemotherapy and biological targeting therapy, and provide new ideas and scientific evidence for the development of novel anti-pancreatic cancer drugs.